Ambrx Biopharma Inc.

NYSE: AMAM · Real-Time Price · USD
28.00
0.02 (0.07%)
At close: Mar 06, 2024, 10:00 PM

Ambrx Biopharma Cash Flow Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022
Period Ending Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Net Income
-22.99M -17.83M -15.3M -10.94M -15.57M -28.84M -22.65M
Depreciation & Amortization
381K 368K 365K 371K 330K 544K 558K
Stock-Based Compensation
4.82M 2.89M 1.94M 1.19M 1.54M 1.88M 1.65M
Other Working Capital
-1.52M 1.55M -4.58M -1.54M -953K 2.51M -7.22M
Other Non-Cash Items
682K 654K 414K 682K 925K 7.58M 3.15M
Deferred Income Tax
526K -28K n/a -220K -233K n/a n/a
Change in Working Capital
-2.3M 796K -382K -3.78M -2.77M 4.3M -8.37M
Operating Cash Flow
-18.88M -13.15M -12.97M -12.7M -15.78M -14.53M -25.66M
Capital Expenditures
-298K -783K n/a -47K -104K -129K -774K
Cash Acquisitions
n/a n/a n/a -8.82M -11.98M n/a n/a
Purchase of Investments
n/a n/a -40.65M -9.42M -12.13M -63.3M n/a
Sales Maturities Of Investments
6.46M 9.96M 70.2M 27.21M 11.98M n/a n/a
Other Investing Acitivies
n/a n/a n/a 8.82M 11.98M n/a n/a
Investing Cash Flow
6.16M 9.18M 29.55M 17.74M -252K -63.43M -774K
Debt Repayment
n/a n/a n/a n/a n/a n/a n/a
Common Stock Repurchased
n/a n/a n/a n/a n/a n/a n/a
Dividend Paid
n/a n/a n/a n/a n/a n/a n/a
Other Financial Acitivies
9.71M 82.65M 77.22M 481K 481K -28K -6K
Financial Cash Flow
9.71M 82.65M 77.22M 481K 481K -28K -6K
Net Cash Flow
-3M 78.68M 93.81M 4.53M -14.56M -77.99M -26.44M
Free Cash Flow
-19.18M -13.93M -12.97M -12.75M -15.88M -14.66M -26.44M